BACKGROUND Inflammation is recognized as a hallmark feature of cancer development and progression. The aim of our study was to investigate the significance of serum nuclear factor kappa-B (NF-κB) levels as a circulating marker in the monitoring of inflammation in breast and colon cancer; to show the relationship between NF-κB with inflammatory parameters as tumour necrosis factor-α (TNF-α), soluble TNF-related apoptosis-inducing ligand (sTRAIL), interleukin-6 (IL-6), pentraxin-3 (PTX-3), procalcitonin (PCT), and C-reactive protein (CRP) levels. METHODS Serum NF-κB, TNF-α, sTRAIL, IL-6, PTX-3, PCT, and serum CRP levels were measured using enzyme-linked immunosorbent assay (ELISA) in 40 patients with breast cancer, 40 patients with colon cancer and 30 healthy controls. RESULTS The serum NF-κB, TNF-α, IL-6, PTX-3, PCT, and serum CRP concentration was significantly higher, and the serum sTRAIL concentration was significantly lower in the patients with breast and colon cancer than in healthy controls. NF-κB was positively correlated with CRP and negatively correlated with sTRAIL. CONCLUSIONS These results suggest that increased NF-κB may decrease the clinical efficacy of sTRAIL in solid tumour cells. There is a relationship between inflammation and carcinogenesis so that the development of cancer occurs with chronic inflammation in breast and colon. The study results have shown that colon and breast cancer patients have increased systemic inflammation, as measured by increased circulating cytokines, and acute-phase proteins, or by abnormalities in circulating cells. NF-κB may combine with other markers of the systemic inflammatory response in prognostic scores in cancer. In addition to surgical resection of the tumour, and conventional radio and chemotherapy for cancer treatment, the use of sTRAIL or other agonists for cancer therapy appeared a new potential therapy.

中文翻译：

---

循环核因子-κ B 介导人类乳腺癌和结肠癌中与癌症相关的炎症。


背景技术炎症被认为是癌症发生和进展的标志特征。我们研究的目的是探讨血清核因子 kappa-B (NF-κB) 水平作为循环标志物在监测乳腺癌和结肠癌炎症中的意义；显示 NF-κB 与肿瘤坏死因子-α (TNF-α)、可溶性 TNF 相关凋亡诱导配体 (sTRAIL)、白介素-6 (IL-6)、pentraxin-3 (PTX-) 等炎症参数之间的关系3）、降钙素原（PCT）和C反应蛋白（CRP）水平。方法 采用酶联免疫吸附法（ELISA）检测 40 例乳腺癌患者、40 例结肠癌患者和 40 例结肠癌患者血清 NF-κB、TNF-α、sTRAIL、IL-6、PTX-3、PCT 和血清 CRP 水平。 30 名健康对照。结果乳腺癌和结肠癌患者血清NF-κB、TNF-α、IL-6、PTX-3、PCT、CRP浓度显着高于健康对照者，血清sTRAIL浓度显着低于健康对照者。 NF-κB与CRP呈正相关，与sTRAIL呈负相关。结论 这些结果表明，NF-κB 的增加可能会降低 sTRAIL 在实体瘤细胞中的临床疗效。炎症与癌变之间存在关联，因此癌症的发生与乳腺和结肠的慢性炎症有关。研究结果表明，结肠癌和乳腺癌患者的全身炎症增加，这是通过循环细胞因子和急性期蛋白增加或循环细胞异常来衡量的。 NF-κB 可能与癌症预后评分中全身炎症反应的其他标志物结合起来。 除了手术切除肿瘤、常规放疗和化疗治疗癌症之外，使用sTRAIL或其他激动剂进行癌症治疗似乎是一种新的潜在疗法。